BACKGROUND: The purpose was to define the rate of local recurrence (LR) and identify prognostic factors for LR in patients with extremity soft-tissue sarcoma (STS) treated with limb-sparing surgery and a pathologically negative re-resection specimen without radiotherapy (RT). METHODS: A review of the prospective sarcoma database identified 200 patients with primary, nonmetastatic, extremity STS treated with limb-sparing surgery between June 1982 and December 2002 who had a pathologically confirmed negative re-resection. None of the patients had adjuvant RT. Univariate and multivariate analyses were performed to determine clinicopathologic factors associated with LR. RESULTS: With a median follow-up of 82 months the 5-year actuarial LR rate was 9%. Factors associated with higher LR rates on univariate and multivariate analysis were older age, stage III presentation, and histology. The 5-year LR rate was 5% for those<50 compared with 15% for those>or=50 (P=.001). For patients with stage III the LR rate was 26% versus 7% for those with stage I/II (P<.001). On multivariate analysis only age>or=50 (relative risk [RR] 3.3; P=.02) and stage III disease (RR 3.4; P=.01) remained significant predictors for LR. When the cohort of patients was divided into 3 groups based on the number of risk factors present, the 5-year LRs were as follows: no risk factors (stage I/II and<50 years old) 4%, 1 risk factor (stage III or>or=50) 12%, and 2 risk factors (stage III and>or=50) 31% (P<.01). CONCLUSIONS: Patients with a pathologically negative re-excision represent a heterogeneous group. Whereas the overall rate of local recurrence at 5 years was 9% for the entire cohort, patients with older age and/or stage III disease had a higher rate of LR. Therefore, treatment decisions especially with regard to adjuvant RT should be individualized and not be based solely on the finding of a negative re-resection. Copyright (c) 2008 American Cancer Society.
BACKGROUND: The purpose was to define the rate of local recurrence (LR) and identify prognostic factors for LR in patients with extremity soft-tissue sarcoma (STS) treated with limb-sparing surgery and a pathologically negative re-resection specimen without radiotherapy (RT). METHODS: A review of the prospective sarcoma database identified 200 patients with primary, nonmetastatic, extremity STS treated with limb-sparing surgery between June 1982 and December 2002 who had a pathologically confirmed negative re-resection. None of the patients had adjuvant RT. Univariate and multivariate analyses were performed to determine clinicopathologic factors associated with LR. RESULTS: With a median follow-up of 82 months the 5-year actuarial LR rate was 9%. Factors associated with higher LR rates on univariate and multivariate analysis were older age, stage III presentation, and histology. The 5-year LR rate was 5% for those<50 compared with 15% for those>or=50 (P=.001). For patients with stage III the LR rate was 26% versus 7% for those with stage I/II (P<.001). On multivariate analysis only age>or=50 (relative risk [RR] 3.3; P=.02) and stage III disease (RR 3.4; P=.01) remained significant predictors for LR. When the cohort of patients was divided into 3 groups based on the number of risk factors present, the 5-year LRs were as follows: no risk factors (stage I/II and<50 years old) 4%, 1 risk factor (stage III or>or=50) 12%, and 2 risk factors (stage III and>or=50) 31% (P<.01). CONCLUSIONS:Patients with a pathologically negative re-excision represent a heterogeneous group. Whereas the overall rate of local recurrence at 5 years was 9% for the entire cohort, patients with older age and/or stage III disease had a higher rate of LR. Therefore, treatment decisions especially with regard to adjuvant RT should be individualized and not be based solely on the finding of a negative re-resection. Copyright (c) 2008 American Cancer Society.
Authors: George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne Journal: J Natl Compr Canc Netw Date: 2005-03 Impact factor: 11.908
Authors: Andrea Ferrari; Yueh-Yun Chi; Gian Luca De Salvo; Daniel Orbach; Bernadette Brennan; R Lor Randall; M Beth McCarville; Jennifer O Black; Rita Alaggio; Douglas S Hawkins; Gianni Bisogno; Sheri L Spunt Journal: Eur J Cancer Date: 2017-04-07 Impact factor: 9.162
Authors: Matthew J Krasin; Andrew M Davidoff; Xiaoping Xiong; Shengjie Wu; Chia-Ho Hua; Fariba Navid; Carlos Rodriguez-Galindo; Bhaskar N Rao; Kelly A Hoth; Michael D Neel; Thomas E Merchant; Larry E Kun; Sheri L Spunt Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-20 Impact factor: 7.038
Authors: V Soyfer; B W Corn; Y Kollender; J Issakov; S Dadia; G Flusser; J Bickels; I Meller; O Merimsky Journal: Br J Radiol Date: 2013-05-24 Impact factor: 3.039
Authors: Javier López-Gómez; Erwin R Flores-Vázquez; Ma Alejandra Salazar-Álvarez; Rodrigo Y Adame; Dorian Y Garcia-Ortega; Mario Cuellar-Hübbe Journal: Int J Surg Case Rep Date: 2017-01-16
Authors: Mohammed Mehdi Hajiabadi; Benito Campos; Oliver Sedlaczek; Elias Khajeh; Mohammadsadegh Nikdad; Andreas von Deimling; Arianeb Mehrabi; Andreas Unterberg; Rezvan Ahmadi Journal: Langenbecks Arch Surg Date: 2020-01-11 Impact factor: 3.445
Authors: Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen Journal: Cancers (Basel) Date: 2020-08-12 Impact factor: 6.639